Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United StatesResearch in context

• Main Authors: Ayodeji Adegunsoye (Author), Rachel Baccile (Author), Thomas J. Best (Author), Victoria Zaksas (Author), Hui Zhang (Author), Rasika Karnik (Author), Bhakti K. Patel (Author), Anthony E. Solomonides (Author), William F. Parker (Author), Julian Solway (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Pulmonary fibrosis is characterized by lung parenchymal destruction and can increase morbidity and mortality. Pulmonary fibrosis commonly occurs following hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary fibrosis risk, we investigated whet...